Navigation Links
Cambrex Reports Fourth Quarter And Full Year 2012 Financial Results
Date:2/6/2013

EAST RUTHERFORD, N.J., Feb. 6, 2013 /PRNewswire/ -- Cambrex Corporation (NYSE: CBM) reports results for the fourth quarter and full year ended December 31, 2012.

Highlights- Fourth quarter sales increased by 4.8% and excluding the impact of foreign currency, sales increased 5.7% compared to the fourth quarter of 2011.  Full year sales increased by 9.2% and increased 12.6% excluding the impact of foreign currency. 

- Fourth quarter EBITDA increased 12.4% to $13.1 million compared to $11.6 million in the fourth quarter of 2011.  Full year EBITDA increased 22.4% to $57.5 million compared to $46.9 million in 2011. 

- Debt, net of cash was $40.4 million at the end of the fourth quarter, an increase of $6.0 million during the quarter.  Debt, net of cash, improved $25.6 million for the full year 2012.

- 2013 sales are expected to increase 8% to 12% compared to 2012, excluding the impact of foreign currency, and EBITDA is expected to increase 8% to 18% to between $62 and $68 million.

"We are pleased with our strong financial results for both the fourth quarter and full year 2012, and look forward to an even stronger 2013," commented Steven M. Klosk, President and Chief Executive Officer of Cambrex.  "Sales increased across all key product categories and EBITDA and cash generation improved significantly year over year.

"We expect 2013 to be our third consecutive year of increased sales and EBITDA and we will be making important capital investments to support continued growth, including a large Phase 3 supply agreement signed during 2012 as well as initiatives in other important product categories.  We continue to be positive about the overall market trends and momentum we see for the business in the current year."

Fourth Quarter 2012 Operating Results – Continuing Op
'/>"/>

SOURCE Cambrex Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Cambrex Reports First Quarter 2012 Results
2. Cambrex To Present At Jefferies 2012 Global Healthcare Conference
3. Cambrex Announces Significant New Supply Agreement
4. Cambrex to Announce Third Quarter 2012 Financial Results on October 31, 2012
5. Cambrex Reports Third Quarter 2012 Financial Results
6. Cambrex To Announce Fourth Quarter 2012 Financial Results On February 6, 2013
7. Qmed, the Leading Global MedTech Industry Resource, Partners with Clarimed, to Provide the Medical Manufacturing and Healthcare Industry with FDA Reports on Adverse Events
8. Sigma-Aldrich (NASDAQ: SIAL) Reports Q1 2012 Diluted EPS of $0.96, With Diluted Adjusted EPS of $0.99. Sales Increase 5% for Q1 2012. Full Year 2012 Diluted Adjusted EPS Outlook of $3.90 to $4.05 Reaffirmed.
9. Kelyniam Global Inc. Reports Record Cranial Implant Revenues in the 1st Quarter of 2012
10. Varian Medical Systems Reports Results for Second Quarter of Fiscal Year 2012
11. Mylan Reports Q1 2012 Adjusted Diluted EPS of $0.52, an 18% Increase Over Prior Year Quarter
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... Japan , July 30, 2015 ... of the study to fulfill the post-marketing commitment ... the Pan European Multi-Database Bladder Cancer Risk ... retrospective matched cohort study, conducted in four European ... HCI) with up to 10 years of follow-up. ...
(Date:7/30/2015)... 30, 2015 Global ENT ... to reach USD 23.01 million in 2022, according to ... base of geriatric population, increasing prevalence of ear, nose, ... of awareness among target customer base are expected serve ... forecast period. According to estimates published by the WHO, ...
(Date:7/30/2015)... LONDON , July 30, 2015 ... devices market ? Which areas are going to grow ... report shows you potential revenues to 2025, assessing data, ... report provides 176 tables, charts, and graphs. ... the future market prospects. Our new study lets you ...
Breaking Medicine Technology:Takeda Announces Completion of the Pioglitazone Post-Marketing Commitment and Submission of Results to the EMA, the FDA and the PMDA 2Takeda Announces Completion of the Pioglitazone Post-Marketing Commitment and Submission of Results to the EMA, the FDA and the PMDA 3Takeda Announces Completion of the Pioglitazone Post-Marketing Commitment and Submission of Results to the EMA, the FDA and the PMDA 4Takeda Announces Completion of the Pioglitazone Post-Marketing Commitment and Submission of Results to the EMA, the FDA and the PMDA 5Takeda Announces Completion of the Pioglitazone Post-Marketing Commitment and Submission of Results to the EMA, the FDA and the PMDA 6ENT Devices Market Size to Reach $23.01 Billion by 2022: Grand View Research, Inc. 2ENT Devices Market Size to Reach $23.01 Billion by 2022: Grand View Research, Inc. 3ENT Devices Market Size to Reach $23.01 Billion by 2022: Grand View Research, Inc. 4ENT Devices Market Size to Reach $23.01 Billion by 2022: Grand View Research, Inc. 5Ophthalmic Devices Market Forecast 2015-2025 - Future Prospects for Leading Companies in Vision Care, Surgical, Diagnostic & Monitoring Devices 2Ophthalmic Devices Market Forecast 2015-2025 - Future Prospects for Leading Companies in Vision Care, Surgical, Diagnostic & Monitoring Devices 3Ophthalmic Devices Market Forecast 2015-2025 - Future Prospects for Leading Companies in Vision Care, Surgical, Diagnostic & Monitoring Devices 4Ophthalmic Devices Market Forecast 2015-2025 - Future Prospects for Leading Companies in Vision Care, Surgical, Diagnostic & Monitoring Devices 5Ophthalmic Devices Market Forecast 2015-2025 - Future Prospects for Leading Companies in Vision Care, Surgical, Diagnostic & Monitoring Devices 6
... BEIJING, Dec. 31, 2010 /PRNewswire-Asia-FirstCall/ -- Lotus Pharmaceuticals, Inc. ... the "Company"), a fast-growing, profitable developer, manufacturer and seller ... China ("PRC"), announced today that the Company will effect ... order to meet minimum share price requirements in connection ...
... WOONSOCKET, R.I., Dec. 31, 2010 CVS Caremark (NYSE: ... into an agreement to acquire the Medicare Part D ... for approximately $1.25 billion.  Universal American is a leading ... New York. The acquisition will more than double the ...
Cached Medicine Technology:Lotus Pharmaceuticals Announces Approval of Reverse Stock Split 2CVS CAREMARK to Purchase Universal American's Medicare Part D Business 2CVS CAREMARK to Purchase Universal American's Medicare Part D Business 3CVS CAREMARK to Purchase Universal American's Medicare Part D Business 4
(Date:7/31/2015)... ... July 31, 2015 , ... BioViva USA, Inc. (“BioViva”), a ... treat aging diseases. , BioViva announces it has begun a fundraiser through Maximum ... Disease (AD) and find a cure. MaxLife will grant 100% of the money raised ...
(Date:7/31/2015)... ME (PRWEB) , ... July 31, 2015 , ... The alarm was ringing. Hugh Chatfield, ... Glancing out of the window, he recalled that his equipment was set up to depict ... tower, he jumped out of bed. , The photo speaks for itself. Chatfield is also ...
(Date:7/31/2015)... CA (PRWEB) , ... July 31, 2015 , ... Awarded ... Hair Restoration is proud to announce that they are the latest recipients of the ... cements their status as one of the worldwide leaders in the science of hair ...
(Date:7/31/2015)... (PRWEB) , ... July 31, 2015 , ... ... selected as a contributor for LeadingAge’s Center for Aging Services Technologies (CAST) Medication ... to help long-term and post-acute care providers understand the benefits of using ...
(Date:7/31/2015)... , ... July 31, 2015 , ... ... Emergency Medicine Practice, and Hospital Medicine Practice, is pleased to announce that it ... a mobile application format available on iPhones, iPads, and Android smartphones and tablets. ...
Breaking Medicine News(10 mins):Health News:BioViva USA, Inc.’s Alzheimer’s Disease Gene Therapy Human Trial 2Health News:BioViva USA, Inc.’s Alzheimer’s Disease Gene Therapy Human Trial 3Health News:Prestigious Medical Award Given To Parsa Mohebi Hair Restoration for Excellence in Hair Transplantation 2Health News:LeadingAge Selects Eldermark Case Study to Highlight Medication Error Reduction Results 2Health News:LeadingAge Selects Eldermark Case Study to Highlight Medication Error Reduction Results 3Health News:EB Medicine Launches Mobile Application for Pediatric Emergency Medicine 2Health News:EB Medicine Launches Mobile Application for Pediatric Emergency Medicine 3
... 6 May 2010 -- Researchers from Cold Spring Harbor Laboratory ... analyzing the genome of single tumor cells. The breakthrough allows ... tumors develop and has the potential to help doctors identify ... from the prostate or a non-invasive lesion in the breast. ...
... May 2010 -- A new study of metastatic breast ... patients have in their blood directly correlates with the ... Cancer Conference in Brussels, Belgium, the results have the ... these patients. Circulating tumor cells --cancer cells found ...
... After menopause, 6 to 10 million women take hormone ... progestin, to replace hormones lost from inactive ovaries. Progestin ... potentially negative effects of estrogen therapy on the uterus. ... evidence has been found that estrogen and progestin in ...
... ... , ... (PRWEB) May 6, 2010 -- CosmoCom the global leader in Contact Center Consolidation ... prestigious 2010 Long Island Software Award (LISA). Presented by the Long Island Software and ...
... ... steady employment in a highly competitive market. In order to gain a competitive edge against ... appearance. Non-surgical med spa treatments can offer many benefits during a job hunt. , ... (PRWEB) May 6, 2010 -- With ...
... ... achieving top performance from GPUs in diverse applications using Monte Carlo simulations can now ... Group (NAG). , ... (Vocus) May 6, 2010 -- Developers and researchers who are interested in achieving top ...
Cached Medicine News:Health News:Genome breakthrough allows scientists to identify and profile tumor cells from very small samples 2Health News:Survival in metastatic breast cancer directly linked to circulating tumor cells 2Health News:Breast cancer metastasis increases after estrogen and progestin hormone therapies, MU study finds 2Health News:CosmoCom Wins Software Award for CosmoHealth 2Health News:CosmoCom Wins Software Award for CosmoHealth 3Health News:Med Spa Treatments Become More Popular as Unemployment Rates Climb 2Health News:Med Spa Treatments Become More Popular as Unemployment Rates Climb 3Health News:More GPU Routines for Technical Research Now Available from Numerical Algorithms Group 2Health News:More GPU Routines for Technical Research Now Available from Numerical Algorithms Group 3
IDS Rapid ANA II System, a microbial identification system....
IDS Rapid STR, a microbial identification system....
IDS Rapid One, a microbial identification system....
IDS Rapid NF Plus, a microbial identification system....
Medicine Products: